Inv16 p13q22 T1616p13q22 Gene Rearrangement Quantitative MRD Monitor Test
Introduction to the Test
The Inv16 p13q22 T1616p13q22 Gene Rearrangement Quantitative MRD Monitor Test is a crucial diagnostic tool in the field of oncology, specifically designed to detect minimal residual disease (MRD) in patients undergoing treatment for cancer. This test utilizes advanced Real Time PCR technology to provide accurate quantification of gene rearrangements that may indicate the presence of residual cancer cells in the body after treatment.
What the Test Measures
This test measures the presence of specific genetic rearrangements associated with certain types of leukemia and other malignancies. By quantifying these genetic markers, healthcare providers can gauge the effectiveness of treatment and make informed decisions regarding further interventions.
Who Should Consider This Test
Patients who have been diagnosed with cancers such as acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) should consider this test, especially if they are in remission or undergoing treatment. Symptoms that may indicate the need for this test include:
- Persistent fatigue
- Unexplained weight loss
- Frequent infections
- Easy bruising or bleeding
Benefits of Taking the Test
Taking the Inv16 p13q22 T1616p13q22 Gene Rearrangement Quantitative MRD Monitor Test offers numerous benefits, including:
- Early detection of residual disease, allowing for timely intervention.
- Assessment of treatment response, aiding oncologists in tailoring therapy.
- Improved patient outcomes through personalized treatment plans.
Understanding Your Results
Results from this test will indicate the level of minimal residual disease present in the patient’s blood or bone marrow. A lower level of detectable MRD suggests a favorable response to treatment, while higher levels may indicate the need for additional therapy. It is essential to discuss the results with your healthcare provider to understand their implications fully.
Test Pricing
| Price Type | Amount (NGN) |
|---|---|
| Discount Price | 150,000 NGN |
| Regular Price | 200,000 NGN |
Booking the Test
To book the Inv16 p13q22 T1616p13q22 Gene Rearrangement Quantitative MRD Monitor Test, please ensure you have a duly filled MRD Requisition form (Form 22) with historical data, as this is mandatory. Samples can be submitted on Mondays or Thursdays by 11 AM, and reports will be available on Wednesdays or Saturdays.
For further information or to schedule your test, please call or WhatsApp us at +2348077798758.
